Histogenics Corp (NASDAQ: HSGX) shares were down 73% of their market value at time of publishing following the release data of its Phase 3 clinical trial of NeoCart that did not meet the primary endpoint of a statistically significant improvement in pain and function in a dual threshold responder analysis one year after treatment as […]
Curis, Inc. (NASDAQ: CRIS) – brief chart analysis for you – lots of room to grow Play on your own risk. About Curis, Inc. Curis, Inc., (NASDAQ: CRIS) a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, […]
We profiled Æterna Zentaris (AEZS) stock as a highly speculative investment opportunity at around $.44. AEZS shares almost doubled in value for the last six weeks and still on their way to over a dollar. Market favored Æterna’s stock with Roth Capital initiation a “Buy” share/price target of $1.75 and even more price goal expectations from the […]
